Arkadiy Yadgarov
Glaucoma Specialist · Atlanta, GANPI 1952677858
Payments from drug & device makers
Across 1,485 payments — averaging $622.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$219K
- AbbVie$174K
- Sight Sciences, Inc.$148K
- Ocular Therapeutix, Inc.$121K
- Bausch & Lomb Americas Inc.$112K
- Alcon$68K
- plus $84K from 26 others
Across 4 payments — averaging $10,063 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sight Sciences, Inc.$39K
- Ocular Therapeutix, Inc.$2K
What the payments were for
- Consulting fees$197,86729%
- Speaking & faculty fees$379,06456%
- Grants$7500%
- Travel & lodging$54,3518%
- Food & beverage$39,4366%
- Education$1470%
- Gifts$1350%
- Entertainment$480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 223 | $218,921 |
| AbbVie(2 entities) | 344 | $173,986 |
| Sight Sciences, Inc. | 211 | $147,990 |
| Ocular Therapeutix, Inc. | 7 | $120,682 |
| Bausch & Lomb Americas Inc. | 197 | $111,570 |
| Alcon | 158 | $68,222 |
| Aerie Pharmaceuticals, Inc. | 77 | $45,671 |
| Ivantis, Inc | 31 | $19,247 |
| NEW World Medical,inc. | 29 | $9,410 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 27 | $4,468 |
| Sun Pharmaceutical Industries Inc. | 56 | $1,503 |
| Novartis | 47 | $562 |
| Harrow Eye, LLC | 9 | $529 |
| Oyster Point Pharma, Inc. | 24 | $521 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $299 |
| Eyepoint US, Inc. | 2 | $250 |
| Amgen(2 entities) | 8 | $193 |
| Rxsight Inc | 6 | $156 |
| Genentech USA, Inc. | 2 | $153 |
| Carl Zeiss Meditec USA, Inc. | 1 | $125 |
| Microsurgical Technology, Inc. | 1 | $116 |
| Iridex Corporation | 2 | $89 |
| Nova Eye, Inc. | 2 | $88 |
| Thea Pharma Inc. | 3 | $84 |
| Akorn Operating Company LLC | 3 | $59 |
| Tarsus Pharmaceuticals, Inc. | 2 | $49 |
| Dompe US, Inc. | 2 | $49 |
| Biotissue Holdings Inc. | 1 | $32 |
| Eyevance Pharmaceuticals LLC | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Omeros Corporation | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYZULTA$113,053
- OMNI(R) SURGICAL SYSTEM (US)$79,697
- Rocklatan$62,723
- Rhopressa$62,605
- DURYSTA$52,288
- Hydrus Microstent$49,276
- LUMIGAN$49,045
- Travoprost Intraocular Implant - iDose$43,680
- SION SURGICAL INSTRUMENT$24,790
- XEN GLAUCOMA TREATMENT SYSTEM$21,452
- iDose$19,778
- COMBIGAN$16,789
- Hydrus$15,995
- ALPHAGAN P$11,875
- iStent inject W$11,407
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$10,309
- Ahmed Glaucoma Valve$8,785
- Kahook Dual Blade$8,785
- Clearpath$8,682
- Streamline$8,682
How this compares
Too few glaucoma specialist providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 335 | $179,023 |
| RestasisCyclosporine | 73 | $64,820 |
| RhopressaNetarsudil Mesylate | 105 | $62,838 |
| XiidraLifitegrast | 61 | $55,505 |
| CombiganBrimonidine Tartrate/Timolol | 124 | $52,504 |
| VyzultaLatanoprostene Bunod | 97 | $45,330 |
| RocklatanNetarsudil Mesylat/Latanoprost | 61 | $40,206 |
| TyrvayaVarenicline Tartrate | 23 | $32,250 |
| ProlensaBromfenac Sodium | 93 | $31,488 |
| IlevroNepafenac | 51 | $21,692 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 120 | $20,470 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,095 | $16,857 |
| CequaCyclosporine | 21 | $16,638 |
| MieboPerfluorohexyloctane/Pf | 21 | $16,105 |
| VevyeCyclosporine | 13 | $13,287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $173,986 | $302,153547 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $111,570 | $116,940179 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $45,671 | $103,044166 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $521 | $32,25023 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $4,468 | $31,48893 claims |
| NovartisIlevro | $562 | $21,69251 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,503 | $16,63821 claims |
| Harrow Eye, LLCVevye | $529 | $13,28713 claims |
| AlconSimbrinza | $68,222 | $8,59829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Atlanta
- Reay BrownAtlanta$29K
- Elma ChangAtlanta$9K
- Jean ParkAtlanta$4K
- Derrick PauAtlanta$3K
- Matthew FabrizioAtlanta$2K
- Morohunranti Oguntoye-OumaAtlanta$500
- Ronak PatelDecatur$7K
- David KimSavannah$4K
- Niraj NathanBuford$2K
- Edward WashingtonNorcross$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.